Drugs / ANCREMONAM
ANCREMONAM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03377426 | Oct 2018 → Oct 2019 | urinary tract infection | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT03354754 | May → Sep 2018 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANCREMONAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206129 ↗ |
| Known as | BOS-228 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206129 ↗ |
| Known as | LYS228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03354754 ↗ |
| Action | Inhibit | “Exposing E. coli cells to LYS228 caused filamentation consistent with impaired cell division.” PMID 30061293 ↗ Sep 2018 |
| Modality | Small molecule | — CHEMBL4206129 ↗ |
| Route | Intravenous | “LYS228 IV infusion every 6 hours” NCT03354754 ↗ |